|
Form 4 Filings | Insider Buys | Significant Buys |
Penny Stocks Insider Buying |
Insider Sales |
| Insider Buy Sell Ratios | Stock Options |
Insider Trading Stock Screener |
Insider Trading Graph View |
Insider Watch |
Insider Trading - Denali Therapeutics Inc. (DNLI)
|
|
"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch What is insider trading>> |
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2019-02-08 Sale |
2019-02-12 6:30 pm |
Denali Therapeutics Inc. | DNLI | Schuth Alexander O. COO |
7,500 | $19.08 | $143,089 | 667,589 (Direct Indirect) |
View |
| 2019-02-01 Sale |
2019-02-05 6:28 pm |
Denali Therapeutics Inc. | DNLI | Ho Carole Chief Medical Officer |
17,500 | $18.72 | $327,589 | 142,615 (Direct Indirect) |
View |
| 2019-02-01 Sale |
2019-02-05 6:27 pm |
Denali Therapeutics Inc. | DNLI | Watts Ryan J. CEO |
18,334 | $18.72 | $343,300 | 2,646,588 (Direct Indirect) |
View |
| 2019-01-09 Sale |
2019-01-11 5:11 pm |
Denali Therapeutics Inc. | DNLI | Schuth Alexander O. COO |
7,500 | $20.37 | $152,750 | 675,089 (Direct Indirect) |
View |
| 2019-01-02 Sale |
2019-01-04 6:54 pm |
Denali Therapeutics Inc. | DNLI | Ho Carole Chief Medical Officer |
14,502 | $19.55 | $283,506 | 143,515 (Direct Indirect) |
View |
| 2019-01-02 Sale |
2019-01-04 6:52 pm |
Denali Therapeutics Inc. | DNLI | Watts Ryan J. CEO |
18,333 | $19.43 | $356,288 | 2,665,921 (Direct Indirect) |
View |
| 2018-12-10 Sale |
2018-12-12 5:27 pm |
Denali Therapeutics Inc. | DNLI | Schuth Alexander O. COO |
7,500 | $20.4 | $153,000 | 682,589 (Direct Indirect) |
View |
| 2018-12-03 Sale |
2018-12-06 5:08 pm |
Denali Therapeutics Inc. | DNLI | Ho Carole Chief Medical Officer |
17,500 | $18.45 | $322,834 | 148,790 (Direct Indirect) |
View |
| 2018-11-27 Sale |
2018-12-06 5:06 pm |
Denali Therapeutics Inc. | DNLI | Watts Ryan J. CEO |
18,333 | $18.43 | $337,938 | 2,689,304 (Direct Indirect) |
View |
| 2018-11-15 Sale |
2018-11-19 5:31 pm |
Denali Therapeutics Inc. | DNLI | Ho Carole Chief Medical Officer |
17,500 | $18.07 | $316,157 | 165,890 (Direct Indirect) |
View |
| 2018-11-13 Sale |
2018-11-15 6:13 pm |
Denali Therapeutics Inc. | DNLI | Watts Ryan J. CEO |
18,334 | $18.09 | $331,664 | 2,742,892 (Direct Indirect) |
View |
| 2018-10-01 Sale |
2018-10-03 6:01 pm |
Denali Therapeutics Inc. | DNLI | Watts Ryan J. CEO |
18,333 | $21.72 | $398,193 | 2,747,638 (Direct Indirect) |
View |
| 2018-10-01 Sale |
2018-10-03 5:59 pm |
Denali Therapeutics Inc. | DNLI | Ho Carole Chief Medical Officer |
17,500 | $21.72 | $380,100 | 183,390 (Direct Indirect) |
View |
| 2018-09-04 Sale |
2018-09-06 5:27 pm |
Denali Therapeutics Inc. | DNLI | Ho Carole Chief Medical Officer |
17,500 | $19.05 | $333,375 | 200,890 (Direct Indirect) |
View |
| 2018-09-04 Sale |
2018-09-06 5:25 pm |
Denali Therapeutics Inc. | DNLI | Watts Ryan J. CEO |
18,333 | $19.06 | $349,427 | 2,765,971 (Direct Indirect) |
View |
| 2018-08-29 Sale |
2018-08-31 5:44 pm |
Denali Therapeutics Inc. | DNLI | Ho Carole Chief Medical Officer |
17,500 | $18.04 | $315,700 | 218,390 (Direct Indirect) |
View |
| 2018-08-29 Sale |
2018-08-31 5:41 pm |
Denali Therapeutics Inc. | DNLI | Watts Ryan J. CEO |
18,334 | $18.05 | $330,929 | 2,784,304 (Direct Indirect) |
View |
| 2017-12-12 Purchase |
2017-12-14 4:09 pm |
Denali Therapeutics Inc. | DNLI | BRATTON DOUGLAS K AKDL L.P. Neuro Line Partners LP Crestline SI (GP) L.P. Crestline Investors Inc. Bratton Capital Management L.P. Bratton Capital Inc. Crestline Management LP 10% Owner |
275,000 | $18 | $4,950,000 | 19,462,500 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2019-02-07 Option Award |
2019-02-11 5:59 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | Schuth Alexander O. COO |
17,000 | $0 | 136,000 (Direct) |
View |
| 2019-02-07 Option Award |
2019-02-11 5:59 pm |
N/A 2029-02-06 |
Denali Therapeutics Inc. | DNLI | Schuth Alexander O. COO |
136,000 | $17.99 | 136,000 (Direct) |
View |
| 2019-02-07 Option Award |
2019-02-11 5:57 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | Ho Carole Chief Medical Officer |
17,000 | $0 | 136,000 (Direct) |
View |
| 2019-02-07 Option Award |
2019-02-11 5:57 pm |
N/A 2029-02-06 |
Denali Therapeutics Inc. | DNLI | Ho Carole Chief Medical Officer |
136,000 | $17.99 | 136,000 (Direct) |
View |
| 2019-02-07 Option Award |
2019-02-11 5:56 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | Krognes Steve E. CFO |
17,000 | $0 | 136,000 (Direct) |
View |
| 2019-02-07 Option Award |
2019-02-11 5:56 pm |
N/A 2029-02-06 |
Denali Therapeutics Inc. | DNLI | Krognes Steve E. CFO |
136,000 | $17.99 | 136,000 (Direct) |
View |
| 2019-02-08 Option Award |
2019-02-11 5:54 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | Watts Ryan J. CEO |
11,031 | $0 | 281,600 (Direct) |
View |
| 2019-02-08 Option Award |
2019-02-11 5:54 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | Watts Ryan J. CEO |
35,200 | $0 | 281,600 (Direct) |
View |
| 2019-02-08 Option Award |
2019-02-11 5:54 pm |
N/A 2029-02-07 |
Denali Therapeutics Inc. | DNLI | Watts Ryan J. CEO |
281,600 | $18.13 | 281,600 (Direct) |
View |
| 2019-02-01 Exercise |
2019-02-05 6:28 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | Ho Carole Chief Medical Officer |
5,775 | $5.28 | 142,615 (Direct) |
View |
| 2019-02-01 Exercise |
2019-02-05 6:28 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | Ho Carole Chief Medical Officer |
730 | $5.28 | 142,615 (Direct) |
View |
| 2019-02-01 Exercise |
2019-02-05 6:28 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | Ho Carole Chief Medical Officer |
3,139 | $5.28 | 142,615 (Direct) |
View |
| 2019-02-01 Exercise |
2019-02-05 6:28 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | Ho Carole Chief Medical Officer |
7,856 | $5.28 | 142,615 (Direct) |
View |
| 2019-02-01 Exercise |
2019-02-05 6:28 pm |
N/A 2026-07-01 |
Denali Therapeutics Inc. | DNLI | Ho Carole Chief Medical Officer |
5,775 | $5.28 | 142,615 (Direct) |
View |
| 2019-02-01 Exercise |
2019-02-05 6:28 pm |
N/A 2026-07-01 |
Denali Therapeutics Inc. | DNLI | Ho Carole Chief Medical Officer |
730 | $5.28 | 142,615 (Direct) |
View |
| 2019-02-01 Exercise |
2019-02-05 6:28 pm |
N/A 2027-03-07 |
Denali Therapeutics Inc. | DNLI | Ho Carole Chief Medical Officer |
3,139 | $5.28 | 142,615 (Direct) |
View |
| 2019-02-01 Exercise |
2019-02-05 6:28 pm |
N/A 2027-03-07 |
Denali Therapeutics Inc. | DNLI | Ho Carole Chief Medical Officer |
7,856 | $5.28 | 142,615 (Direct) |
View |
| 2019-01-02 Exercise |
2019-01-04 6:54 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | Ho Carole Chief Medical Officer |
5,775 | $5.28 | 143,515 (Direct) |
View |
| 2019-01-02 Exercise |
2019-01-04 6:54 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | Ho Carole Chief Medical Officer |
5,950 | $5.28 | 143,515 (Direct) |
View |
| 2019-01-02 Exercise |
2019-01-04 6:54 pm |
N/A 2026-07-01 |
Denali Therapeutics Inc. | DNLI | Ho Carole Chief Medical Officer |
5,775 | $5.28 | 143,515 (Direct) |
View |
| 2019-01-02 Exercise |
2019-01-04 6:54 pm |
N/A 2026-07-01 |
Denali Therapeutics Inc. | DNLI | Ho Carole Chief Medical Officer |
5,950 | $5.28 | 143,515 (Direct) |
View |
| 2018-11-27 Gift |
2018-12-06 5:06 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | Watts Ryan J. CEO |
40,000 | $0 | 2,689,304 (Indirect) |
View |
| 2018-11-06 Option Award |
2018-11-08 5:37 pm |
N/A 2028-11-05 |
Denali Therapeutics Inc. | DNLI | Cook Jennifer E. Director |
50,044 | $17.08 | 50,044 (Direct) |
View |
| 2018-10-02 Exercise |
2018-10-03 5:58 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | Schuth Alexander O. COO |
1,184 | $5.28 | 685,089 (Direct) |
View |
| 2018-10-02 Exercise |
2018-10-03 5:58 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | Schuth Alexander O. COO |
5,859 | $9.6 | 685,089 (Direct) |
View |
| 2018-10-02 Exercise |
2018-10-03 5:58 pm |
N/A 2027-03-07 |
Denali Therapeutics Inc. | DNLI | Schuth Alexander O. COO |
1,184 | $5.28 | 685,089 (Direct) |
View |
| 2018-10-02 Exercise |
2018-10-03 5:58 pm |
N/A 2027-08-21 |
Denali Therapeutics Inc. | DNLI | Schuth Alexander O. COO |
5,859 | $9.6 | 685,089 (Direct) |
View |
| 2018-08-20 Option Award |
2018-08-22 5:45 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | Schuth Alexander O. COO |
11,286 | $0 | 11,286 (Direct) |
View |
| 2018-08-20 Option Award |
2018-08-22 5:43 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | Ho Carole Chief Medical Officer |
11,286 | $0 | 11,286 (Direct) |
View |
| 2018-08-20 Option Award |
2018-08-22 5:42 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | Krognes Steve E. CFO |
11,286 | $0 | 11,286 (Direct) |
View |
| 2018-06-22 Exercise |
2018-06-26 5:38 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | Schuth Alexander O. COO |
5,918 | $5.28 | 685,089 (Direct) |
View |
| 2018-06-22 Exercise |
2018-06-26 5:38 pm |
N/A 2027-03-07 |
Denali Therapeutics Inc. | DNLI | Schuth Alexander O. COO |
5,918 | $5.28 | 685,089 (Direct) |
View |
| 2018-06-13 Option Award |
2018-06-15 6:31 pm |
N/A 2028-06-12 |
Denali Therapeutics Inc. | DNLI | NELSEN ROBERT Director, 10% Owner |
27,830 | $18.92 | 27,830 (Direct) |
View |
| 2018-06-13 Option Award |
2018-06-15 6:30 pm |
N/A 2028-06-12 |
Denali Therapeutics Inc. | DNLI | Tessier-Lavigne Marc Director |
27,830 | $18.92 | 27,830 (Direct) |
View |
| 2018-06-13 Option Award |
2018-06-15 6:29 pm |
N/A 2028-06-12 |
Denali Therapeutics Inc. | DNLI | FLATLEY JAY T Director |
27,830 | $18.92 | 27,830 (Direct) |
View |
| 2018-06-13 Option Award |
2018-06-15 6:28 pm |
N/A 2028-06-12 |
Denali Therapeutics Inc. | DNLI | Schenkein David P Director |
27,830 | $18.92 | 27,830 (Direct) |
View |
| 2018-06-13 Option Award |
2018-06-15 6:27 pm |
N/A 2028-06-12 |
Denali Therapeutics Inc. | DNLI | Cole Douglas G. Director |
27,830 | $18.92 | 27,830 (Direct) |
View |
| 2018-06-13 Option Award |
2018-06-15 6:27 pm |
N/A 2028-06-12 |
Denali Therapeutics Inc. | DNLI | SATO VICKI L Director |
27,830 | $18.92 | 27,830 (Direct) |
View |
| 2018-03-16 Option Award |
2018-03-20 6:29 pm |
N/A 2028-03-15 |
Denali Therapeutics Inc. | DNLI | Klein Peter S Director |
37,954 | $21.53 | 37,954 (Direct) |
View |
| 2018-02-26 Option Award |
2018-02-28 7:57 pm |
N/A 2028-02-25 |
Denali Therapeutics Inc. | DNLI | Ho Carole Chief Medical Officer |
180,000 | $22.16 | 180,000 (Direct) |
View |
| 2018-02-26 Option Award |
2018-02-28 7:56 pm |
N/A 2028-02-25 |
Denali Therapeutics Inc. | DNLI | Krognes Steve E. CFO |
180,000 | $22.16 | 180,000 (Direct) |
View |
| 2018-02-26 Option Award |
2018-02-28 7:55 pm |
N/A 2028-02-25 |
Denali Therapeutics Inc. | DNLI | Schuth Alexander O. COO |
180,000 | $22.16 | 180,000 (Direct) |
View |
| 2017-12-13 Option Award |
2018-02-28 7:53 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | Watts Ryan J. CEO |
5 | $20.47 | 2,802,638 (Direct) |
View |
| 2017-12-13 Option Award |
2018-02-28 7:53 pm |
N/A 2028-02-25 |
Denali Therapeutics Inc. | DNLI | Watts Ryan J. CEO |
300,000 | $22.16 | 2,802,638 (Direct) |
View |
| 2017-12-12 Conversion |
2017-12-14 4:09 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | BRATTON DOUGLAS K AKDL L.P. Neuro Line Partners LP Crestline SI (GP) L.P. Crestline Investors Inc. Bratton Capital Management L.P. Bratton Capital Inc. Crestline Management LP 10% Owner |
14,499,999 | $0 | 19,462,500 (Indirect) |
View |
| 2017-12-12 Conversion |
2017-12-14 4:09 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | BRATTON DOUGLAS K AKDL L.P. Neuro Line Partners LP Crestline SI (GP) L.P. Crestline Investors Inc. Bratton Capital Management L.P. Bratton Capital Inc. Crestline Management LP 10% Owner |
2,500,000 | $0 | 19,462,500 (Indirect) |
View |
| 2017-12-12 Conversion |
2017-12-14 4:09 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | BRATTON DOUGLAS K AKDL L.P. Neuro Line Partners LP Crestline SI (GP) L.P. Crestline Investors Inc. Bratton Capital Management L.P. Bratton Capital Inc. Crestline Management LP 10% Owner |
1,875,000 | $0 | 19,462,500 (Indirect) |
View |
| 2017-12-12 Conversion |
2017-12-14 4:09 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | BRATTON DOUGLAS K AKDL L.P. Neuro Line Partners LP Crestline SI (GP) L.P. Crestline Investors Inc. Bratton Capital Management L.P. Bratton Capital Inc. Crestline Management LP 10% Owner |
743,599 | $0 | 19,462,500 (Indirect) |
View |
| 2017-12-12 Conversion |
2017-12-14 4:09 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | BRATTON DOUGLAS K AKDL L.P. Neuro Line Partners LP Crestline SI (GP) L.P. Crestline Investors Inc. Bratton Capital Management L.P. Bratton Capital Inc. Crestline Management LP 10% Owner |
128,200 | $0 | 19,462,500 (Indirect) |
View |
| 2017-12-12 Conversion |
2017-12-14 4:09 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | BRATTON DOUGLAS K AKDL L.P. Neuro Line Partners LP Crestline SI (GP) L.P. Crestline Investors Inc. Bratton Capital Management L.P. Bratton Capital Inc. Crestline Management LP 10% Owner |
240,000 | $0 | 19,462,500 (Indirect) |
View |
| 2017-12-12 Conversion |
2017-12-14 4:09 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | BRATTON DOUGLAS K AKDL L.P. Neuro Line Partners LP Crestline SI (GP) L.P. Crestline Investors Inc. Bratton Capital Management L.P. Bratton Capital Inc. Crestline Management LP 10% Owner |
14,499,999 | $0 | 19,462,500 (Indirect) |
View |
| 2017-12-12 Conversion |
2017-12-14 4:09 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | BRATTON DOUGLAS K AKDL L.P. Neuro Line Partners LP Crestline SI (GP) L.P. Crestline Investors Inc. Bratton Capital Management L.P. Bratton Capital Inc. Crestline Management LP 10% Owner |
2,500,000 | $0 | 19,462,500 (Indirect) |
View |
| 2017-12-12 Conversion |
2017-12-14 4:09 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | BRATTON DOUGLAS K AKDL L.P. Neuro Line Partners LP Crestline SI (GP) L.P. Crestline Investors Inc. Bratton Capital Management L.P. Bratton Capital Inc. Crestline Management LP 10% Owner |
1,875,000 | $0 | 19,462,500 (Indirect) |
View |
| 2017-12-12 Conversion |
2017-12-14 4:09 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | BRATTON DOUGLAS K AKDL L.P. Neuro Line Partners LP Crestline SI (GP) L.P. Crestline Investors Inc. Bratton Capital Management L.P. Bratton Capital Inc. Crestline Management LP 10% Owner |
743,599 | $0 | 19,462,500 (Indirect) |
View |
| 2017-12-12 Conversion |
2017-12-14 4:09 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | BRATTON DOUGLAS K AKDL L.P. Neuro Line Partners LP Crestline SI (GP) L.P. Crestline Investors Inc. Bratton Capital Management L.P. Bratton Capital Inc. Crestline Management LP 10% Owner |
128,200 | $0 | 19,462,500 (Indirect) |
View |
| 2017-12-12 Conversion |
2017-12-14 4:09 pm |
N/A N/A |
Denali Therapeutics Inc. | DNLI | BRATTON DOUGLAS K AKDL L.P. Neuro Line Partners LP Crestline SI (GP) L.P. Crestline Investors Inc. Bratton Capital Management L.P. Bratton Capital Inc. Crestline Management LP 10% Owner |
240,000 | $0 | 19,462,500 (Indirect) |
View |
|
© 2005-2019 SecForm4.Com All rights reserved. Archives: 2019 2018 2017 2016 2015 2014 ... Fri, 22 Feb 2019 21:14:57 -0600 |
SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC). Terms of Use | Privacy Statement | |